Bis(ethyl)norspermine potentiates the apoptotic activity of the pure antiestrogen ICI 182780 in breast cancer cells

Oncology Reports

Volumn 13, Issue 1, 2005, Pages 101-108

  Balabhadrapathruni, Srivani ^a   Santhakumaran, Latha M ^a   Thomas, T J ^a   Shirahata, Akira ^b   Gallo, Michael A ^a   Thomas, Thresia ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b JOSAI UNIVERSITY   (Japan)

Author keywords

Antiestrogen; Bis(ethyl)norspermine; Breast cancer

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; CASP8 PROTEIN, HUMAN; CASPASE; CASPASE 8; DRUG DERIVATIVE; ESTRADIOL; FULVESTRANT; N(1),N(11) DIETHYLNORSPERMINE; N(1),N(11)-DIETHYLNORSPERMINE; POLYAMINE; PROTEIN BCL 2; SPERMINE;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 8; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; POLYAMINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SPERMINE;

EID: 21644450924     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.1.101     Document Type: Article

References (49)

1. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR and Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of the proliferation and cell phenotype. Endocrinology 144: 4562-4574, 2003. (Pubitemid 37204856)
2. Budtz PE: Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen. Cell Prolif 32: 289-302, 1999.
3. MacGregor JI and Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-196, 1998.
4. Sak K and Everaus H: Nongenomic effects of 17β-estradiol-diversity of membrane binding sites. J Steroid Biochem Mol Biol 88: 323-335, 2004. (Pubitemid 38625597)
5. Jordan VC: Tamoxifen: a personal retrospective. Lancet Oncol 1: 43-49, 2000.
6. De Cupis A, Schettini G and Favoni RE: New vs old fashioned estradiol antagonists in mammary carcinoma: in vitro and in vivo pharmacological approaches. Pharmacol Res 39: 335-344, 1999. (Pubitemid 29263900)
7. Assikis VJ and Jordan VC: Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet 49: 241-257, 1995.
8. Ellis M: Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9 S3: 20-26, 2004.
9. Howell AOC, Morris C and Wakeling AE: ICI182780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer 89: 817-825, 2000.
10. Osborne C, Coronado-Heinsohn ER and Hilsenbeck SG: Comparison of the effects of the pure steroidal antiestrogens with those of tamoxifen in a model of human breast cancer. J. Natl Cancer Inst 87: 746-750, 1995.
11. Bross PF, Cohen MH, Williams GA and Pazdur R: FDA drug approval summaries: fulvestrant. Oncologist 7: 477-480, 2002. (Pubitemid 36008996)
12. Glikman PL, Manni A, Bartholomew M and Demers L: Polyamine involvement in basal and estradiol-stimulated insulin-like growth factor I secretion and action in breast cancer cells in culture. J Steroid Biochem Mol Biol 37: 1-10, 1990. (Pubitemid 20385630)
13. Thomas T and Thomas TJ: Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications. Breast Cancer Res Treat 29: 189-201, 1994. (Pubitemid 24112620)
14. Thomas T and Thomas TJ: Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58: 244-258, 2001. (Pubitemid 32217356)
15. Thomas T and Thomas TJ: Polyamine metabolism and cancer. J Cell Mol Med 7: 113-126, 2003. (Pubitemid 37123597)
16. Megosh L, Gilmour SK, Rosson D, Soler AP, Blessing M, Sawicki JA and O'Brien TG: Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res 55: 4205-4209, 1995.
17. Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P and Penafiel R: Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clin Cancer Res 5: 2035-2041, 1999. (Pubitemid 29399255)
18. Shah N, Thomas TJ, Lewis JS, Klinge CM, Shirahata A, Gelinas C and Thomas T: Regulation of estrogenic and nuclear factor κB functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells. Oncogene 20: 1715-2179, 2001.
19. Manni A, Washington S, Griffith JW, Verderame MF, Mauger D, Demers LM, Samant RS and Welch DR: Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis 19: 95-105, 2002. (Pubitemid 34264079)
20. Thomas T, Kiang DT, Janne OA and Thomas TJ: Variations in amplification and expression of the ornithine decarboxylase gene in human breast cancer cell lines. Breast Cancer Res Treat 19: 257-267, 1991.
21. Smith MK, Goral MA, Wright JH Matrisian LM, Morris RJ, Klein-Szanto AJ and Gilmour SK: Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res 57: 2104-2108, 1997. (Pubitemid 27247020)
22. Thomas T, Balabhadrapathruni S, Gallo MA and Thomas TJ: Development of polyamine analogs as cancer therapeutic agents. Oncol Res 13: 123-135, 2002. (Pubitemid 38168454)
23. Porter CW and Bergeron RJ: Regulation of polyamine biosynthetic activity by spermidine and spermine analogs-a novel antiproliferative strategy. Adv Exp Med Biol 250: 677-690, 1988.
24. 11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin Cancer Res 9: 5922-5928, 2003.
25. Faaland CA, Thomas TJ, Balabhadrapathruni S, Langer T, Mian S, Shirahata A, Gallo MA and Thomas T: Molecular correlates of the action of bis(ethyl)polyamines in breast cancer cell growth inhibition and apoptosis. Biochem Cell Biol 78: 415-426, 2000.
26. Davidson NE, Mank AR, Prestigiacomo LJ, Bergeron RJ and Casero RA Jr: Growth inhibition of hormone-responsive and -resistant human breast cancer cells in culture by N1, N12-bis(ethyl)spermine. Cancer Res 53: 2071-2075, 1993. (Pubitemid 23145728)
27. He Y, Suzuki T, Kashiwagi K, Kusuma-Eguchi K, Shirahata A and Igarashi K: Correlation between the inhibition of cell growth by bis(ethyl)polyamine analogues and the decrease in the function of mitochondria. Eur J Biochem 221: 391-398, 1994. (Pubitemid 24120584)
28. Igarashi K, Koga K, He Y, Shimogori T, Ekimoto H, Kashiwagi K and Shirahata A: Inhibition of the growth of various human and mouse tumor cells by 1,15-bis(ethylamino)-4,8,12-triazapentadecane. Cancer Res 55: 2615-2619, 1995.
29. Thomas T and Thomas TJ: Regulation of cyclin B1 by estradiol and polyamines in MCF-7 breast cancer cells. Cancer Res 54: 1077-1084, 1994. (Pubitemid 24085466)
30. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
31. Balabhadrapathruni S, Thomas TJ, Yurkow EJ, Amenta PS and Thomas T: Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells. Oncol Rep 7: 3-12, 2000.
32. Simstein R, Burow M, Parker A, Weldon C and Beckman B: Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med 228: 995-1003, 2003. (Pubitemid 37222167)
33. Orrenius S: Mitochondrial regulation of apoptotic cell death. Toxicol Lett 149: 19-23, 2004.
34. Janicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998. (Pubitemid 28183012)
35. McCloskey DE, Casero RA Jr, Woster PM and Davidson NE: Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. Cancer Res 55: 3233-3236, 1995.
36. Hu RH and Pegg AE: Rapid induction of apoptosis by deregulated uptake of polyamine analogues. Biochem J 328: 307-316, 1997.
37. Huang Y, Hager ER, Phillips DL, Dunn VR, Hacker A, Frydman B, Kink JA, Valasinas AL, Reddy VK, Marton LJ, Casero RA Jr and Davidson NE: A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. Clin Cancer Res 9: 2769-2777, 2003. (Pubitemid 36842123)
38. Hegardt C, Johannsson OT and Oredsson SM: Rapid caspase-dependent cell death in cultured human breast cancer cells induced by the polyamine analogue N1, N11-diethylnorspermine. Eur J Biochem 269: 1033-1039, 2002. (Pubitemid 34175425)
39. Lim KB, Ng CY, Ong CK, Ong CS, Tran E, Nguyen TT, Chan GM and Huynh H: Induction of apoptosis in mammary gland by a pure anti-estrogen ICI 182780. Breast Cancer Res Treat 68: 127-138, 2001. (Pubitemid 32964310)
40. Diel P, Smolnikar K and Michna H: The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 58: 87-97, 1999. (Pubitemid 30032479)
41. Ellis PA, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE and Dowsett M: Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 72: 608-613, 1997. (Pubitemid 27356161)
42. Perillo BSA, Abbondanza C and Palumbo G: 17β-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two-estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901, 2000. (Pubitemid 30183508)
43. Chen Y, Kramer DL, Diegelman P, Vujcic S and Porter CW: Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res 61: 6437-6444, 2001. (Pubitemid 32783249)
44. Dalla Via L, Salvi M, Di Noto V, Stefanelli C and Toninello A: Membrane binding and transport of N-aminoethyl-1,2-diamino ethane (dien) and N-aminopropyl-1,3-diamino propane (propen) by rat liver mitochondria and their effects on membrane permeability transition. Mol Membr Biol 21: 109-118, 2004. (Pubitemid 38524369)
45. Thorburn A: Death receptor-induced cell killing. Cell Signal 16: 139-144, 2004.
46. 11-diethylnorspermine retards S phase progression within one cell cycle. Eur J Biochem 267: 4157-4164, 2000.
47. Kramer DL, Vujcic S, Diegelman P, White C, Black JD and Porter CW: Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res 59: 1278-1286, 1999. (Pubitemid 29136259)
48. Ha HC, Woster PM and Casero RA Jr. Unsymmetrically substituted polyamine analogue induces caspase-independent programmed cell death in Bcl-2-overexpressing cells. Cancer Res 58: 2711-2714, 1998. (Pubitemid 28311895)
49. Rhodes DR, Barrette TR, Rubin MA, Ghosh D and Chinnaiyan AM: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427-4433, 2002. (Pubitemid 34827303)